I-Mab remakes itself, with plans for Hong Kong listing, retinal R&D, and a new name

I-Mab Biopharma announced a slew of changes after the US market closed on Thursday, including acquiring a retinal disease drug, naming a new CFO, and planning a dual listing in Hong Kong. The Rockville, MD ...